SLC5A2 and nephrolithiasis: A meta-analysis of five clinical trials involving over 11 million patients found nephrolithiasis occurred in 1.27% of those taking SGLT2 inhibitors versus 1.56% in control groups, representing a 40% decreased risk compared with placebo and a 34% decreased risk compared with active comparators like GLP-1 receptor agonists or DPP-4 inhibitors [202].